Rivus Pharmaceuticals

Rivus Pharmaceuticals is a private, clinical-stage biotech founded in 2019 and headquartered in Durham, North Carolina. The company is pioneering a new class of oral therapeutics based on mitochondrial uncoupling and GLP-1 agonism to treat obesity and its comorbidities. Its lead asset, HU6, has successfully completed three Phase 2 trials, demonstrating efficacy in MASLD, MASH, and HFpEF. Rivus is advancing a pipeline that includes a differentiated GLP-1 candidate, positioning it in the large and rapidly growing obesity and metabolic disease market.

Oral small molecules leveraging mitochondrial uncoupling and GLP-1 agonism for sustained, fat-selective, muscle-preserving weight loss.

Rivus competes in the crowded and rapidly evolving obesity/MASH therapeutics market, dominated by injectable GLP-1 agonists from Novo Nordisk and Eli Lilly. It faces competition from other companies developing oral GLP-1s, other mitochondrial uncouplers, and novel mechanisms. Differentiation on muscle preservation and oral delivery is critical.